Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).
Mark A. Schroeder, MD
Advertisement
Articles by Mark A. Schroeder, MD
Mark A. Schroeder, MD, discusses therapies currently available and being investigated to treat patients with graft-versus-host disease.
Advertisement
Latest Updated Articles
Dr. Schroeder on Treatment Options for GVHDPublished: February 28th 2020 | Updated:
Dr. Schroeder on the Importance of JAK Inhibition in GVHDPublished: May 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5